Miro Sciences advances StemSmart towards Crohn’s trial after TGA inspection

TGA inspection completed ahead of Crohn’s trial

Miro Sciences Limited (ASX:MSX) has reached a manufacturing milestone for StemSmart, with the Therapeutic Goods Administration completing its inspection of Q-Gen Cell Therapeutics in Brisbane. The inspection supports the company’s preparations to supply product for a planned Phase 2 trial in refractory Crohn’s disease across Australia and the United States.

That is meaningful progress for a cell therapy programme, where manufacturing readiness is a necessary part of moving towards clinical testing. It is not, however, a product approval, a clinical trial approval or confirmation that StemSmart has received TGA licensure. Miro’s announcement also does not disclose the inspection outcome beyond its completion.

Q-Gen to manufacture StemSmart clinical supply

Q-Gen, located within QIMR Berghofer in Brisbane, holds a TGA licence for cell therapy manufacture and operates 13 cleanrooms dedicated to cell manufacturing and quality control. Miro says the facility has more than 25 years’ experience in cell therapy manufacturing and is intended to support the technology transfer and scale-up of StemSmart for the proposed study.

StemSmart is derived from adult donor bone marrow-sourced mesenchymal stem cells developed at Royal Perth Hospital. Its patented manufacturing process is designed to improve therapeutic activity and modulate immune responses associated with severe inflammatory disease. Miro points to early indications from a previous Phase 2 refractory Crohn’s trial, but the company’s next study remains a further evaluation of safety and preliminary efficacy rather than evidence of an established treatment benefit.

FDA feedback and CRO appointment set the clinical timetable

The manufacturing update arrives after Miro appointed Southern Star Research to conduct the planned Phase 2 trial and reported positive feedback from a US Food and Drug Administration pre-Investigational New Drug meeting in October. Taken together, those announcements show activity across manufacturing, regulatory planning and trial operations, although each step remains conditional on the approvals needed to start the study.

Miro is targeting trial initiation by the end of calendar 2026. The next material markers are likely to be confirmation of any follow-up from the TGA inspection, completion of applicable regulatory requirements and evidence that the clinical programme has moved from preparation into patient recruitment.